https://orcid.org/0000-0001-8366-5101
Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Josiah Ryman, Jessica Weaver, Ka Lai Yee & Jeffrey R. Sachs. (2022) Predicting effectiveness of the V114 vaccine against invasive pneumococcal disease in children. Expert Review of Vaccines 21:10, pages 1515-1521.
Read now
Read now
Tianyan Hu, Thomas Weiss, Goran Bencina, Kwame Owusu-Edusei & Tanaz Petigara. (2021) Comprehensive value assessments for new pediatric pneumococcal conjugate vaccines. Journal of Medical Economics 24:1, pages 1083-1086.
Read now
Read now
Articles from other publishers (6)
Salini Mohanty, Kristen Feemster, Kalvin C Yu, Janet A Watts & Vikas Gupta. (2023)
Trends in
Streptococcus pneumoniae
Antimicrobial Resistance in US Children: A Multicenter Evaluation
. Open Forum Infectious Diseases 10:3.
Crossref
Crossref
Yasunori Ishihara, Haruo Kuroki, Hidenobu Hidaka, Kazuyuki Iwai, Keiko Wan, Masayoshi Shirakawa & Miyuki Sawata. (2023) Safety and immunogenicity of a 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A Phase I study (V114-028). Human Vaccines & Immunotherapeutics 19:1.
Crossref
Crossref
Androniki Bili, Scott Dobson, Jeffrey Quinones, Wanatpreeya Phongsamart, Peninnah Oberdorfer, Pope Kosalaraksa, Ron Dagan, Peter Richmond, Marissa Wilck, Waldimir Vallejos, Christine Nunn, Richard McFetridge, Gretchen Tamms, Rong Fu, Robert Lupinacci, Luwy Musey, Natalie Banniettis & Kara Bickham. (2023) A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION). Vaccine 41:3, pages 657-665.
Crossref
Crossref
Kristen Feemster & Thomas Weiss. (2022) Letter to the Editor Regarding “Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age”. Infectious Diseases and Therapy 12:1, pages 291-294.
Crossref
Crossref
Liping Huang, Matt Wasserman, Lindsay Grant, Raymond Farkouh, Vincenza Snow, Adriano Arguedas, Erica Chilson, Reiko Sato & Johnna Perdrizet. (2022) Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States. Vaccine 40:33, pages 4700-4708.
Crossref
Crossref
Matt D. Wasserman, Johnna Perdrizet, Lindsay Grant, Kyla Hayford, Shubhra Singh, Paranjoy Saharia, Emily K. Horn & Raymond A. Farkouh. (2021) Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age. Infectious Diseases and Therapy 10:4, pages 2701-2720.
Crossref
Crossref